I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270
I8S-MC-JUAB - ClinicalTrials.gov - NCT02857270
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participants must NOT
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.
Trial Summary
Conditions the trial is for
Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
What the trial is testing?
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib
Could I receive a Placebo?
no
Enrollment Goal
245
Trial Dates
September 2016 - September 2021
Trial Phase
1
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have advanced, unresectable or metastatic cancer (solid tumors)
Participants must NOT
Participant must not have known HIV infection or hepatitis A, B, or C
Participant must not have current blood cancers, acute or chronic leukemia
Participant must not have previously completed or withdrawn from this study or any other study investigating an ERK1/2 inhibitor - Female participant must not be pregnant, breastfeeding, or planning to become pregnant
Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study, including interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy. Part C4 NRAS Melanoma: have previously completed or withdrawn from a study investigating a MEK inhibitor.
Trial Summary
Conditions the trial is for
Advanced Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Melanoma, Non-small Cell Lung Cancer
What the trial is testing?
LY3214996, Midazolam, Abemaciclib, Nab-paclitaxel, Cetuximab, Encorafenib
Could I receive a Placebo?
no
Enrollment Goal
245
Trial Dates
September 2016 - September 2021
Trial Phase
1
Trial Locations
Hide locations not currently recruiting